|
|
Volumn 10, Issue 6, 2009, Pages 393-394
|
|
Is there an inherent limit to acute migraine treatment efficacy?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AZEPINE DERIVATIVE;
CALCITONIN GENE RELATED PEPTIDE RECEPTOR;
DIPEPTIDE;
IMIDAZOLE DERIVATIVE;
N (6 (2,3 DIFLUOROPHENYL) 2 OXO 1 (2,2,2 TRIFLUOROETHYL)AZEPAN 3 YL) 4 (2 OXO 2,3 DIHYDRO 1H IMIDAZO(4,5 B)PYRIDIN 1 YL)PIPERIDINE 1 CARBOXAMIDE;
N-(6-(2,3-DIFLUOROPHENYL)-2-OXO-1-(2,2,2-TRIFLUOROETHYL)AZEPAN-3-YL)-4-(2-OXO-2,3-DIHYDRO-1H-IMIDAZO(4,5-B)PYRIDIN-1-YL)PIPERIDINE-1-CARBOXAMIDE;
OLCEGEPANT;
QUINAZOLINE DERIVATIVE;
SEROTONIN AGONIST;
TRYPTAMINE DERIVATIVE;
BIOASSAY;
CLINICAL TRIAL;
DRUG ADMINISTRATION;
DRUG ANTAGONISM;
HUMAN;
METABOLISM;
METHODOLOGY;
MIGRAINE;
NOTE;
PATHOPHYSIOLOGY;
STANDARD;
TIME;
TREATMENT OUTCOME;
AZEPINES;
CLINICAL TRIALS AS TOPIC;
DIPEPTIDES;
DRUG ADMINISTRATION SCHEDULE;
ENDPOINT DETERMINATION;
HUMANS;
IMIDAZOLES;
MIGRAINE DISORDERS;
QUINAZOLINES;
RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE;
SEROTONIN AGONISTS;
TIME FACTORS;
TREATMENT OUTCOME;
TRYPTAMINES;
|
|
EID: 77950501374
PISSN: None
EISSN: 11292377
Source Type: Journal
DOI: 10.1007/s10194-009-0162-y Document Type: Note |
|
Times cited : (5)
|
|
References (0)
|
